Should I buy or sell Krystal Biotech stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks .

What is Krystal Biotech's stock price target for 2024?

9 equities research analysts have issued 12-month price targets for Krystal Biotech's shares. Their KRYS share price targets range from $118.00 to $160.00. On average, they expect the company's share price to reach $146.56 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts .

How have KRYS shares performed in 2023?

Krystal Biotech's stock was trading at $79.22 at the beginning of the year. Since then, KRYS stock has increased by 34.1% and is now trading at $106.26. View the best growth stocks for 2023 here .

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our KRYS earnings forecast .

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings results on Monday, November, 6th. The company reported $2.79 earnings per share for the quarter, topping the consensus estimate of ($1.10) by $3.89. The firm earned $8.60 million during the quarter, compared to analysts' expectations of $6.29 million. The company's quarterly revenue was up 8500.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.17) EPS.

What ETFs hold Krystal Biotech's stock?

ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD) , Franklin Genomic Advancements ETF (HELX) , ALPS Medical Breakthroughs ETF (SBIO) , Alpha Architect U.S. Quantitative Momentum ETF (QMOM) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC) . IQ Chaikin U.S. Small Cap ETF (CSML) .

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE) , Allena Pharmaceuticals (ALNA) , Gilead Sciences (GILD) , Sorrento Therapeutics (SRNE) , Corbus Pharmaceuticals (CRBP) , VBI Vaccines (vbiv) , Verastem (VSTM) , CRISPR Therapeutics (CRSP) , Editas Medicine (EDIT) and NVIDIA (NVDA) .

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (9.32%), Redmile Group LLC (7.10%), Lord Abbett & CO. LLC (2.38%), Jennison Associates LLC (1.22%), Morgan Stanley (1.02%) and Skandinaviska Enskilda Banken AB publ (0.87%). Insiders that own company stock include Andrew C Orth, Daniel Janney , Dino A Rossi , Kathryn Romano , Krish S Krishnan and Suma Krishnan . View institutional ownership trends .

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

Krystal Biotech Stock Price, News & Analysis (NASDAQ:KRYS)

$106.26

+2.03 (+1.95%)

(As of 12/1/2023 ET)

Compare

Today's Range: $103.69
▼
$106.30
50-Day Range: $96.00
▼
$122.15
52-Week Range: $69.81
▼
$132.68

Volume: 188,759 shs
Average Volume: 364,454 shs
Market Capitalization: $3.00 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $146.56

Krystal Biotech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 37.9% Upside
$146.56 Price Target
Short Interest: Bearish
7.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: 1.16
Based on 3 Articles This Week
Insider Trading: Selling Shares
$3.18 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.89) to ($0.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

152nd out of 957 stocks

Biological Products, Except Diagnostic Industry

21st out of 157 stocks

3.5

Analyst's Opinion

Consensus Rating
Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $146.56, Krystal Biotech has a forecasted upside of 37.9% from its current price of $106.26.
Amount of Analyst Coverage
Krystal Biotech has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.34% of the outstanding shares of Krystal Biotech have been sold short.
Short Interest Ratio / Days to Cover
Krystal Biotech has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in Krystal Biotech has recently decreased by 1.43%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Krystal Biotech does not currently pay a dividend.
Dividend Growth
Krystal Biotech does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Krystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Krystal Biotech is -0.87.

3.4

News and Social Media Coverage

News Sentiment
Krystal Biotech has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Krystal Biotech this week, compared to 3 articles on an average week.
Search Interest
1 people have searched for KRYS on MarketBeat in the last 30 days.
MarketBeat Follows
6 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,180,750.00 in company stock.
Percentage Held by Insiders
17.00% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.30% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Krystal Biotech are expected to grow in the coming year, from ($3.89) to ($0.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Krystal Biotech is -72.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Krystal Biotech is -72.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Krystal Biotech has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Krystal Biotech Stock (NASDAQ:KRYS)

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

KRYS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KRYS Stock News Headlines

December 3, 2023 | americanbankingnews.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of "Buy" from Analysts

November 27, 2023 | markets.businessinsider.com

Krystal Biotech Says EMA Validated MAA For VYJUVEK For Dystrophic Epidermolysis Bullosa

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 23, 2023 | morningstar.com

Krystal Biotech Inc KRYS

November 22, 2023 | finance.yahoo.com

Goldman Sachs Says These 2 Healthcare Stocks Have up to 130% Upside Potential

November 20, 2023 | msn.com

Goldman Sachs Initiates Coverage of Krystal Biotech (KRYS) with Buy Recommendation

November 20, 2023 | msn.com

Goldman starts Krystal Biotech at buy, cites Vyjuvek launch

November 10, 2023 | finance.yahoo.com

This Stock Has Quadrupled in 5 Years. Can It Do It Again?

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 9, 2023 | finance.yahoo.com

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

November 7, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Cigna (CI), Krystal Biotech (KRYS) and MacroGenics (MGNX)

November 7, 2023 | insidermonkey.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2023 Earnings Call Transcript

November 7, 2023 | finance.yahoo.com

Q3 2023 Krystal Biotech Inc Earnings Call

November 7, 2023 | finance.yahoo.com

Investors push Krystal Biotech (NASDAQ:KRYS) 11% lower this week, company's increasing losses might be to blame

November 6, 2023 | forbes.com

For A Change There’s Optimism About A Gene Therapy’s Commercialization—Vyjuvek For Wound Care

November 6, 2023 | msn.com

Krystal Biotech GAAP EPS of $2.79 beats by $3.46, revenue of $8.6M beats by $2.31M

November 6, 2023 | finance.yahoo.com

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023 | finance.yahoo.com

Krystal Biotech Inc (KRYS) Announces Q3 2023 Financial Results

November 3, 2023 | msn.com

Krystal Biotech Q3 2023 Earnings Preview

October 30, 2023 | finance.yahoo.com

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

October 25, 2023 | benzinga.com

Krystal Biotech Stock (NASDAQ:KRYS), Analyst Ratings, Price Targets, Predictions

October 25, 2023 | msn.com

Cantor starts Krystal Biotech at overweight, cites Vyjuvek launch

October 25, 2023 | nasdaq.com

Cantor Fitzgerald Initiates Coverage of Krystal Biotech (KRYS) with Overweight Recommendation

October 21, 2023 | finance.yahoo.com

KRYS Oct 2023 110.000 call

September 28, 2023 | finance.yahoo.com

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

September 25, 2023 | finance.yahoo.com

Krystal Biotech, Inc. (NASDAQ:KRYS): Are Analysts Optimistic?

September 22, 2023 | msn.com

FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408

See More Headlines

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KRYS
CUSIP: N/A
CIK: 1711279
Web: www.krystalbio.com
Phone: (412) 586-5830
Fax: N/A
Employees: 210
Year Founded: 2017

Price Target and Rating

Average Stock Price Target: $146.56
High Stock Price Target: $160.00
Low Stock Price Target: $118.00
Potential Upside/Downside: +37.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-139,980,000.00
Net Margins: N/A
Pretax Margin: -348.43%
Return on Equity: -21.45%
Return on Assets: -20.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 21.10
Quick Ratio: 20.91

Sales & Book Value

Annual Sales: $8.56 million
Price / Sales: 350.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $26.80 per share
Price / Book: 3.96

Miscellaneous

Outstanding Shares: 28,206,000
Free Float: 23,411,000
Market Cap: $3.00 billion
Optionable: Not Optionable
Beta: 0.84

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Krish S. Krishnan M.B.A. (Age 58)
M.S., Founder, Chairman, President & CEO
Comp: $1.07M
Ms. Suma M. Krishnan (Age 58)
Founder, COO, President of R&D and Director
Comp: $789.92k
Ms. Kathryn A. Romano (Age 41)
Executive VP & Chief Accounting Officer
Comp: $528.87k
Ms. Meg Dodge
Vice President of Investor Relations & Corporate Communications
Mr. John Karakkal
Vice President of North American Sales & Marketing
Mr. Josh Suskin
Director of Human Resources & Operations
Dr. Hubert C. Chen M.D. (Age 54)
Senior Vice President of Clinical Development
Mr. Laurent Goux
Senior VP & GM of Europe
Mr. Ram Kamineni
Senior VP of CMC & Technical Operations
Mr. David Chien
Senior Vice President of Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KRYS Stock Analysis - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings or view top-rated stocks.
What is Krystal Biotech's stock price target for 2024?: 9 equities research analysts have issued 12-month price targets for Krystal Biotech's shares. Their KRYS share price targets range from $118.00 to $160.00. On average, they expect the company's share price to reach $146.56 in the next year. This suggests a possible upside of 37.9% from the stock's current price.
View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts.
How have KRYS shares performed in 2023?: Krystal Biotech's stock was trading at $79.22 at the beginning of the year. Since then, KRYS stock has increased by 34.1% and is now trading at $106.26.
View the best growth stocks for 2023 here.
When is Krystal Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our KRYS earnings forecast.
How were Krystal Biotech's earnings last quarter?: Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings results on Monday, November, 6th. The company reported $2.79 earnings per share for the quarter, topping the consensus estimate of ($1.10) by $3.89. The firm earned $8.60 million during the quarter, compared to analysts' expectations of $6.29 million. The company's quarterly revenue was up 8500.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.17) EPS.
What ETFs hold Krystal Biotech's stock?: ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ Chaikin U.S. Small Cap ETF (CSML).

What other stocks do shareholders of Krystal Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).
When did Krystal Biotech IPO?: (KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.
Who are Krystal Biotech's major shareholders?: Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (9.32%), Redmile Group LLC (7.10%), Lord Abbett & CO. LLC (2.38%), Jennison Associates LLC (1.22%), Morgan Stanley (1.02%) and Skandinaviska Enskilda Banken AB publ (0.87%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends.
How do I buy shares of Krystal Biotech?: Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KRYS) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial